Alcaftadine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Alcaftadine" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

447^th place

338^th place

2web.archive.org

1^st place

1^st place

2^nd place

2^nd place

1prnewswire.com

406^th place

258^th place

doi.org

Greiner JV, Edwards-Swanson K, Ingerman A (January 2011). "Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%". Clinical Ophthalmology. 5: 87–93. doi:10.2147/OPTH.S15379. PMC 3037035. PMID 21339800.
Ono SJ, Lane K (February 2011). "Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis". Drug Design, Development and Therapy. 5: 77–84. doi:10.2147/DDDT.S15788. PMC 3038998. PMID 21340041.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Lastacaft (alcaftadine) Ophthalmic Solution NDA #022134". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 3 December 2013. Retrieved 10 June 2020.
"Drug Approval Package: Lastacaft (alcaftadine) Ophthalmic Solution NDA #022134". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 10 June 2020.

fda.gov

"Alcaftadine" (PDF). Office of Clinical Pharmacology Review. U.S. Food and Drug Administration. 17 November 2009.^{[dead link]}
"Lastacaft (alcaftadine ophthalmic solution 0.25%)" (PDF). Drug Use Review. U.S. Food and Drug Administration (FDA). 21 June 2012. Archived from the original (PDF) on 15 February 2017.

nih.gov

dailymed.nlm.nih.gov

"Lastacaft- alcaftadine solution/ drops". DailyMed. 1 August 2015. Retrieved 10 June 2020.
"Lastacaft- alcaftadine solution/ drops". DailyMed. 10 August 2022. Retrieved 20 May 2024.

ncbi.nlm.nih.gov

Greiner JV, Edwards-Swanson K, Ingerman A (January 2011). "Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%". Clinical Ophthalmology. 5: 87–93. doi:10.2147/OPTH.S15379. PMC 3037035. PMID 21339800.
Ono SJ, Lane K (February 2011). "Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis". Drug Design, Development and Therapy. 5: 77–84. doi:10.2147/DDDT.S15788. PMC 3038998. PMID 21340041.

pubmed.ncbi.nlm.nih.gov

Greiner JV, Edwards-Swanson K, Ingerman A (January 2011). "Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%". Clinical Ophthalmology. 5: 87–93. doi:10.2147/OPTH.S15379. PMC 3037035. PMID 21339800.
Ono SJ, Lane K (February 2011). "Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis". Drug Design, Development and Therapy. 5: 77–84. doi:10.2147/DDDT.S15788. PMC 3038998. PMID 21340041.

prnewswire.com

"Now Available Over the Counter, Lastacaft Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours". PR Newswire (Press release). 15 March 2022. Retrieved 18 May 2024.

web.archive.org

"Drug Approval Package: Lastacaft (alcaftadine) Ophthalmic Solution NDA #022134". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 3 December 2013. Retrieved 10 June 2020.
"Lastacaft (alcaftadine ophthalmic solution 0.25%)" (PDF). Drug Use Review. U.S. Food and Drug Administration (FDA). 21 June 2012. Archived from the original (PDF) on 15 February 2017.